Physician profile
Daniel Rivlin
NPI 1073518692
$3,409.13
in general payments reported to CMS, 2019-2025
33 companies · $209 in 2025
The $209 reported for 2025 was less than what a typical Dermatopathology (Dermatology) provider received nationally (typical 2025 total: $251).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $794 · 2020: $396 · 2021: $605 · 2022: $732 · 2023: $324 · 2024: $349 · 2025: $209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $882.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $881.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $401.05 | 2019-2025 | Rinvoq |
| Stemline Therapeutics INC. | $341.36 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $278.88 | 2019-2025 | Dupixent, Libtayo |
| Hill Dermaceuticals, INC. | $261.97 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $249.97 | 2019-2025 | Jublia, Arazlo, Cabtreo |
| Genentech USA, INC. | $245.47 | 2019-2024 | Erivedge |
| Almirall LLC | $202.25 | 2021-2025 | Klisyri, Seysara |
| Leo Pharma INC. | $164.06 | 2019-2021 | |
| Organogenesis INC. | $145.42 | 2021-2025 | Puraply Wound Matrix |
| Amgen INC. | $143.70 | 2019-2020 | |
| Genzyme Corporation | $133.19 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $121.83 | 2019-2023 | |
| Incyte Corporation | $85.64 | 2021-2023 | Opzelura |
| Pfizer INC. | $67.65 | 2021-2023 | |
| Kerecis Limited | $58.07 | 2024-2025 | Kerecis Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $57.92 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $52.97 | 2023-2024 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $39.74 | 2023 | |
| Sebela Pharmaceuticals INC. | $34.58 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $31.94 | 2019 | |
| Celgene Corporation | $30.84 | 2019 | |
| Viiv Healthcare Company | $29.92 | 2021 | |
| Smith+Nephew, INC. | $26.58 | 2022 | |
| Acera Surgical, INC. | $23.94 | 2022 | |
| Allergan, INC. | $22.87 | 2022 | |
| Galderma Laboratories, L.P. | $22.47 | 2022 | |
| Biofrontera INC. | $22.45 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Tempus Ai, INC | $20.86 | 2024 | Merlin Test |
| Mayne Pharma Commercial LLC | $20.69 | 2019 | |
| Dermira, INC. | $20.53 | 2019 | |
| Sun Pharmaceutical Industries INC. | $20.29 | 2021 | |
| Myriad Genetic Laboratories, INC. | $18.67 | 2021 | |
| Paratek Pharmaceuticals, INC. | $11.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Rivlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.